Coleman KE, Yin Y, Lui SKL, Keegan S, Fenyo D, Smith DJ, et al. USP1-trapping lesions as a source of DNA replication stress and genomic instability. Nature Communications. 2022;13:1740. https://doi.org/10.1038/s41467-022-29369-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D’Andrea AD, et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Molecular Cell. 2005;17:331–9. https://doi.org/10.1016/j.molcel.2005.01.008.

Article  CAS  PubMed  Google Scholar 

Oestergaard VH, Langevin F, Kuiken HJ, Pace P, Niedzwiedz W, Simpson LJ, et al. Deubiquitination of FANCD2 is required for DNA crosslink repair. Mol Cell. 2007;28:798–809. https://doi.org/10.1016/j.molcel.2007.09.020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohn MA, Kowal P, Yang K, Haas W, Huang TT, Gygi SP, et al. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol Cell. 2007;28:786–97. https://doi.org/10.1016/j.molcel.2007.09.031.

Article  CAS  PubMed  Google Scholar 

Liang F, Miller AS, Longerich S, Tang C, Maranon D, Williamson EA, et al. DNA requirement in FANCD2 deubiquitination by USP1-UAF1-RAD51AP1 in the Fanconi anemia DNA damage response. Nature Communications. 2019;10:2849. https://doi.org/10.1038/s41467-019-10408-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rennie ML, Arkinson C, Chaugule VK, Walden H. Cryo-EM reveals a mechanism of USP1 inhibition through a cryptic binding site. Sci Adv. 2022;8:eabq6353. https://doi.org/10.1126/sciadv.abq6353.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cadzow L, Brenneman J, Tobin E, Sullivan P, Nayak S, Ali JA, et al. The USP1 inhibitor KSQ-4279 overcomes PARP inhibitor resistance in homologous recombination-deficient tumors. Cancer Res. 2024;84:3419–34. https://doi.org/10.1158/0008-5472.Can-24-0293.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Korenev G, Yakukhnov S, Druk A, Golovina A, Chasov V, Mirgayazova R, et al. USP7 inhibitors in cancer immunotherapy: current status and perspective. Cancers. 2022;14:5539.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keijzer N, Sakoltchik J, Majumder K, van Lil N, El Oualid F, Fish A, et al. USP1/UAF1 targets polyubiquitinated PCNA with an exo-cleavage mechanism that can temporarily enrich for monoubiquitinated PCNA. Nat Commun. 2025;16:6991. https://doi.org/10.1038/s41467-025-61768-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ryu E, Yoo J, Kang M-S, Ha NY, Jang Y, Kim J, et al. ATAD5 functions as a regulatory platform for Ub–PCNA deubiquitination. Proc Natl Acad Sci USA. 2024;121:e2315759121. https://doi.org/10.1073/pnas.2315759121.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dharadhar S, Clerici M, van Dijk WJ, Fish A, Sixma TK. A conserved two-step binding for the UAF1 regulator to the USP12 deubiquitinating enzyme. J Struct Biol. 2016;196:437–47. https://doi.org/10.1016/j.jsb.2016.09.011.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H, Lim Kah S, Kim H, Hinds Thomas R, Jo U, Mao H, et al. Allosteric Activation of Ubiquitin-Specific Proteases by β-Propeller Proteins UAF1 and WDR20. Molecular Cell. 2016;63:249 – 60. https://doi.org/10.1016/j.molcel.2016.05.031.

Dharadhar S, van Dijk WJ, Scheffers S, Fish A, Sixma TK. Insert L1 is a central hub for allosteric regulation of USP1 activity. EMBO Rep. 2021;22:e51749. https://doi.org/10.15252/embr.202051749.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Foster BM, Wang Z, Schmidt CK. DoUBLing up: ubiquitin and ubiquitin-like proteases in genome stability. Biochem J. 2024;481:515–45. https://doi.org/10.1042/bcj20230284.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu X, Guo R, Xu D. The emergence of a unified mechanism in the Fanconi anemia pathway. Genome Instability Disease. 2021;2:281–91. https://doi.org/10.1007/s42764-021-00053-y.

Article  CAS  Google Scholar 

Arkinson C, Chaugule VK, Toth R, Walden H. Specificity for deubiquitination of monoubiquitinated FANCD2 is driven by the N-terminus of USP1. Life Sci Alliance. 2018;1:e201800162. https://doi.org/10.26508/lsa.201800162.

Article  PubMed  PubMed Central  Google Scholar 

Yin J, Schoeffler AJ, Wickliffe K, Newton K, Starovasnik MA, Dueber EC, et al. Structural insights into WD-Repeat 48 activation of Ubiquitin-Specific protease 46. Structure. 2015;23:2043–54. https://doi.org/10.1016/j.str.2015.08.010.

Article  CAS  PubMed  Google Scholar 

Li H, Lim KS, Kim H, Hinds TR, Jo U, Mao H, et al. Allosteric activation of Ubiquitin-Specific proteases by β-Propeller proteins UAF1 and WDR20. Mol Cell. 2016;63:249–60. https://doi.org/10.1016/j.molcel.2016.05.031.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rennie ML, Arkinson C, Chaugule VK, Toth R, Walden H. Structural basis of FANCD2 deubiquitination by USP1-UAF1. bioRxiv. 2020:2020.12.05.412924. https://doi.org/10.1101/2020.12.05.412924.

Chen S, Liu Y, Zhou H. Advances in the development Ubiquitin-Specific peptidase (USP) inhibitors. Int J Mol Sci. 2021;22:4546. https://www.mdpi.com/1422-0067/22/9/4546.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao H, Xi Z, Dai J, Xue J, Guan X, Zhao L, et al. Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options. Mol Cancer. 2024;23:88. https://doi.org/10.1186/s12943-024-02005-y.

Article  PubMed  PubMed Central  Google Scholar 

Zhu H, Zhang T, Wang F, Yang J, Ding J. Structural insights into the activation of USP46 by WDR48 and WDR20. Cell Discov. 2019;5:34. https://doi.org/10.1038/s41421-019-0102-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim Y, Ha NY, Kang MS, Ryu E, Yi G, Yoo J, et al. ATAD5-BAZ1B interaction modulates PCNA ubiquitination during DNA repair. Nat Commun. 2024;15:10496. https://doi.org/10.1038/s41467-024-55005-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen J, Dexheimer TS, Ai Y, Liang Q, Villamil MA, Inglese J, et al. Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol. 2011;18:1390–400. https://doi.org/10.1016/j.chembiol.2011.08.014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mistry H, Hsieh G, Buhrlage SJ, Huang M, Park E, Cuny GD, et al. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther. 2013;12:2651–62. https://doi.org/10.1158/1535-7163.Mct-13-0103-t.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Torrado C, Ashton NW, D’Andrea AD, Yap TA. USP1 inhibition: a journey from target discovery to clinical translation. Pharmacol Ther. 2025;271:108865. https://doi.org/10.1016/j.pharmthera.2025.108865.

Article  CAS  PubMed  Google Scholar 

Yap TA, Lakhani NJ, Patnaik A, Lee EK, Gutierrez M, Moore KN, et al. First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with Olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations. J Clin Oncol. 2024;42:3005. https://doi.org/10.1200/JCO.2024.42.16_suppl.3005.

Article